Biography:
In 1984 I started the company (Digene) that pioneered HPV testing for cancer using DNA from cervical specimens. It is believed to still be the most widely used DNA test for early detection/prevention of cancer. In 1998 I performed one of the first IO Phase I/II trials; it closed meeting all endpoints and showing variable but sometimes striking cancer reduction without toxicity. I now focus on early detection methods for other cancers and am developing the first system to enrich trans-renal DNA from urine to increase sensitivity and convenience of liquid biopsy testing to complement and/or replace methods using blood.
Modeling a novel SMARTer design using an optimizing diagnostic: quantitative evaluation of improved patient outcome and sample size reduction, and implications for lower clinical trial costs and facilitating registration
Evaluation of uProcess for detection of oncogene sequences in buffer and urine by qPCR following 3-minute capture and 5-minute purification procedure